Express Mail Label No.: EL961889430US

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number INFORMATION DISCLOSURE Filing Date June 21, 2006 STATEMENT BY APPLICANT First Named Inventor Michel SCHNEIDER (Use as many sheets as necessary) Art Unit TBA Examiner Name TRA 2 Attomey Docket Number Sheet 1 of BR-036 PUS 01

			U.S.	PATENT DOCUMENTS	
Examiner nitials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (Finown)}	MINIPODETTTT		Figures Appear
	AA	US 4,276,885 B1 .	07-07-1981	Rasor Associates, Inc.	
	AB	US 4,888,398 B1	12-19-1989	Battelle Memorial Institute	
	AC	US 5,271,928 B1	12-21-1993	Sintetica S.A.	
	AD	US 5,413,774 B1	05-09-1995	Bracco International B.V.	
	AE	US 5,445,813 B1	08-29-1995	Bracco International B.V.	
	AF	US 5,545,395 B1	08-13-1996	Bracco Research S.A.	
	AG	US 5,531,980 B1	07-02-1996	Bracco International B.V.	
	AH	US 5,556,610 B1	09-17-1996	Bracco Research S.A.	
	Al	US 5,562,099 B1	10-08-1996	Massachusetts Institute of Technology; The Penn State Research Foundation	
	AJ	US 5,597,549 B1	01-28-1997	Bracco International B.V.	
	AK	US 5,605,673 B1	02-25-1997	Alliance Pharmaceutical Corp.	
	AL	US 5,711,933 B1	01-27-1998	Bracco International B.V.	
	AM	US 5,827,504 B1	10-27-1998	Bracco Research S.A.	
	AN	US 6,139,819 B1	10-31-2000	ImaRx Pharmaceutical Corp.	
	AO	US 6,221,337 B1	04-24-2001	Nycomed Imaging AS	
	AP	US 6,331,289 B1	12-25-2001	Bracco Research S.A.	
	AQ	US 6,333,021 B1	12-18-2001	Nycomed Imaging AS	

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)	MM-DD-YYYY			T ⁶				
	BA	EP 0130935 B1	04-15-1987	Battelle Memorial Institute						
	BB	EP 0324938 B1	11-18-1993	Molecular Biosystems, Inc.						
1	BC	EP 0554213 B1	01-15-1997	Bracco International B.V.						
	BD	EP 0804251 B1	09-25-2002	Bracco Research S.A.						
	BE	EP 1228770 A1	08-07-2002	Bracco Research S.A.						
	BF	EP 1228770 B1	07-13-2005	Bracco Research S.A.						
	BG	WO 87/03891	07-02-1987	Battelle Memorial Institute						
	вн	WO 91/15244 A2	10-17-1991	Sintetica S.A.						
	BI	WO 94/09829 A1	05-11-1994	Sintetica S.A.	1					

Examiner Signature	/Leah Schlientz/	Date Considered	07/31/2010

*EXAMINER: Intial if retereonic considered, whether or not classion is in conformance with MPEP 603. Daws fee through citation #561.8 Self-feelings and not considered. Include copy of this form with next communication to applicant. "Applicants with expectation designation channels (prioring see Kinds Codes of USPTO Patient Documents at https://www.news.edu.org/. Expectation feels and the second counters, the indication of the year of the regin of the Emperor must preced the serial number of the patient document by the appropriate symbols as indicated on the document with off the regin of the Emperor must precede the serial number of the patient document by the appropriate symbols as indicated on the document with off the serial obscurate the serial number of the patient document. "And of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible." Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CR 1, 97 and 1,98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CPT al. 14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the governey to complete this form and/or suggestions for exidual, gits burden, should be sent to the Chief Information and Trademark Office, P.O. Box 1450, Alexandria, VA.22314-1450, DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22314-150.

1

Express Mail Label No.: EL961889430US

Sheet

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRA

BR-036 PUS 01

2

Ωf

Examiner Name

Attorney Docket Number

	FOREIGN PATENT DOCUMENTS									
Examiner Initals*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		Applicant of Cited Document		T ⁶				
	BJ	WO 94/28873 A1	12-22-1994	Unger et al.						
	BK	WO 95/23615 A1	09-08-1995	Nycomed Imaging AS						
	BL	WO 97/29783 A1	08-21-1997	Nycomed Imaging AS						
	BM	WO 98/18501 A2	05-07-1998	Nycomed Imaging AS		_				
	BN	WO 99/39738 A1	08-12-1999	Bracco Research S.A.						
	во	WO 99/53963 A1	10-28-1999	Nycomed Imaging AS						
	BP	WO 99/55383 A2	11-04-1999	Nycomed Imaging AS						
	BQ	WO 02/055544 A2	07-18-2002	Dyax Corp.						
	BR	WO 03/015831 A1	02-27-2003	Bristol-Myers Squibb Pharma Company						
	BS	WO 03/074005 A2	09-12-2003	Dyax Corp. and Bracco International B.V.						
	ВТ	WO 03/084574 A1	10-16-2003	Bracco International B.V. and Dyax Corp.						
	BU	WO 04/069284 A2	08-19-04	Bracco Research S.A.						
	BV	WO 04/069284 A3	08-19-04	Bracco Research S.A.						

Examiner Signature	/Leah Schlientz/	Date Considered	07/31/2010

Localises: Intelligent the properties of the pro

This collection or information is required by 37 CR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Conditionality is operated by 35 US. C. 122 and 37 CRF 1.14. This collection is estimated to be bours to complete, including apthering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/ors suggestions for reducing this bursten, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Box

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Express Mail Label No.: EL961889430US

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substit	tute for form 1449/PTO			Complete if Known		
				Application Number	TBA 5066	
	DRMATION DIS			Filing Date	June 21, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Michel SCHNEIDER	
	(Use as many sheets as	neces	earv)	Art Unit	ТВА	
	(Coo ao many onocio ao	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,	Examiner Name	TBA	
Sheet	1	of	1	Attorney Docket Number	BR-036 PUS 01	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	ar Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number(s), publisher, city and/or country where published.					
	CA	KATHERINE C. GRABAR et al: "Preparation and Characterization of Au Colloid Monolayers" Analytical Chemistry, Vol. 67, No. 4, February 15, 1995, pp. 735-743				
		M. MALMSTEN, "Surfactants and Polymers in Drug Delivery", 2002, Ch. 2, pp. 19-50, Ch. 4, pp. 87-131, Marcel Dekker Inc. Ed.				
	СС	G.W. KABALKA et al., "Gadolinium-labeled liposomes containing paramagnetic amphipathic agents: targeted MRI contrast agents for the liver", Magnetic Resonance in Medicine, 1988, pp. 89-95, Vol. 8, Academic Press, Inc.				
	CD	Edited by R. R. C. New "Liposomes, a practical approach", 1989, pp. 45-55, Oxford University Press, Oxford, New York, Tokyo				
	CE	PCT Search Report for PCT/IB2004/004230, mail date 05-30-2005				
	CF	PCT Written Opinion of the ISA, mail date 05-30-2005				

Examiner		Date	
Signature	/Leah Schlientz/	Considered	07/31/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMENTE Initial interesting comparises, writtening of the cuseautre as incommentation in mercer locus.

Application unique existent designation in unique policional, "Application is to judice a check mark here it finglish Translation is attached. "Application is unique existent origination in attached." This collection of information is required by 37 CR I 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPITO to process) an application. Confidentiality is governed by 32 U.S. C. 12 and 27 CF I 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 32 U.S. C. 12 and 27 CF I 1.14. This collection is estimated to take 2 hours to complete, including the confidence of the conf gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, alexandria, VA 22313-1450.